Northland Starts Aridis Pharmaceuticals (ARDS) at Outperform

Northland Capital Markets analyst Carl Byrnes initiates coverage on Aridis Pharmaceuticals (NASDAQ: ARDS) with a Outperform rating and a price target of $40.00.

The analyst comments "Aridis represents a pure-play innovator focused on developing monoclonal antibody, mAb, immunotherapies for life threatening bacterial infections. The Company's lead candidate, AR-301 for S. aureus HAP/VAP, is entering pivotal P3 clinical trials in 4Q18 with anticipated interim data in 2H19. AR-105 for P. aeruginosa HAP/VAP is currently in P2 trials with anticipated interim data in 1H19."

For an analyst ratings summary and ratings history on Aridis Pharmaceuticals click here. For more ratings news on Aridis Pharmaceuticals click here.

Shares of Aridis Pharmaceuticals closed at $9.70 yesterday.

You May Also Be Interested In

• Bernstein SocGen Group Starts Terawulf Inc. (WULF) at Outperform
• TD Cowen Starts Merlin Labs (MRLN) at Buy, 'Flight Autonomy Provider W/ Optionality'
• Raymond James Assumes GE Vernova (GEV) at Market Perform